IP Library Granted Patent US 9,327,010
Granted Patent B2
US 9,327,010 · App. 11/411,745 · Granted May 3, 2016

Compositions and methods for promoting hemostasis and other physiological activities

Inventors: Rutledge Ellis-Behnke (Canton, MA); Shuguang Zhang (Lexington, MA); Gerald Schneider (Somerville, MA); Kwok-Fai So (Pokfulam, HK); David Tay (Pokfulam, HK); Yu-Xiang Liang (Pokfulam, HK)
Assignees: Massachusetts Institute of Technology; Versitech Limited
A61K38/08A61K9/0019A61K38/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,327,010
App. No.
11/411,745
Granted
May 3, 2016
Kind
B2
Abstract

Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.

Claims (18)

1. A formulation for making an in vivo barrier structure, comprising:

self-assembling peptides,

wherein the self-assembling peptides consist of a sequence of from 8 to 16 amino acid residues conforming to one or more of Formulas I-IV:

((Xaa neu -Xaa + ) x (Xaa neu -Xaa − ) y ) n   (I)

((Xaa neu -Xaa − ) x (Xaa neu -Xaa + ) y ) n   (II)

((Xaa + -Xaa neu ) x (Xaa − Xaa neu ) y ) n   (III)

((Xaa − -Xaa neu ) x (Xaa + Xaa neu ) y ) n   (IV)

wherein Xaa neu represents alanine or leucine; Xaa + represents arginine or lysine; Xaa − represents aspartic acid or glutamic acid; x and y are integers having a value of 1 or 2, or 4, independently; and n is an integer having a value of 1-4,

wherein the self-assembling peptides are in an effective concentration to self-assemble upon contact with physiological fluids at an exposed surgical incision site or an exposed wound site of an animal to form a macroscopic structure that inhibits or prevents passage of bodily fluid through the structure,

wherein the barrier structure is formed by application of a powder or an aqueous solution of the self-assembling peptides to the exposed surgical incision site or exposed wound site,

wherein the solution has a total concentration of less than 5 mM Li+, Na+, K+, and Cs+ ions and a concentration of self-assembling peptides between 1.0% weight to volume and 4.0% weight to volume inclusive.

2. The formulation for making the barrier structure of claim 1 , wherein the aqueous solution of the peptides further comprises a pharmaceutically acceptable carrier and/or a non-fibrous agent.

3. The formulation for making the barrier structure of claim 1 , further comprising a therapeutic agent, prophylactic agent, diagnostic agent, a pharmaceutically acceptable diluent, filler, or oil.

4. The formulation of claim 3 , further comprising anti-inflammatories, vasoconstrictors, anti-infectives, anesthetics, growth factors, cells, organic compounds, biomolecules, coloring agents, vitamins, or metals.

5. The formulation of claim 1 , wherein the self-assembling peptides are in an aqueous solution at a concentration of between 1.0% weight to volume to 3.0% weight to volume, inclusive.

6. The formulation of claim 5 , wherein the self-assembling peptides are in an aqueous solution at a concentration of between 2.0% weight to volume to 3.0% weight to volume.

7. The formulation of claim 1 ,

wherein the self-assembling peptides comprise the amino acid sequence RADARADARADARADA (SEQ ID NO: 1).

Assignments (4)
CONFIRMATORY LICENSE Recorded Jul 5, 2016
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039252/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2007
From: ELLIS-BEHNKE, RUTLEDGE; SCHNEIDER, GERALD E.; ZHANG, SHUGUANG
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 019898/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2007
From: LIANG, YU-XIANG; SO, KWOK-FAI; TAY, DAVID
To: THE UNIVERSITY OF HONG KONG
Reel/Frame 019898/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2007
From: THE UNIVERSITY OF HONG KONG
To: VERSITECH LIMITED
Reel/Frame 019898/0876 →
Continuity (3)
Provisional Application 60674612 · Apr 25, 2005
Provisional Application 60758827 · Jan 13, 2006
Related Publication 20070203062A1 · Aug 30, 2007